RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy

Biomed Res Int. 2018 Aug 26:2018:7675286. doi: 10.1155/2018/7675286. eCollection 2018.

Abstract

Receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs) are the key factors indicating a danger to the organism. They recognize the microbial origin pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). The primary response induced by PAMPs or DAMPs is inflammation. Excessive stimulation of the innate immune system occurs in arterial wall with the participation of effector cells. Persistent adaptive responses can also cause tissue damage and disease. However, inflammation mediated by the molecules innate responses is an important way in which the adaptive immune system protects us from infection. The specific detection of PAMPs and DAMPs by host receptors drives a cascade of signaling that converges at nuclear factor-κB (NF-κB) and interferon regulatory factors (IRFs) and induces the secretion of proinflammatory cytokines, type I interferon (IFN), and chemokines, which promote direct killing of the pathogen. Therefore, signaling of these receptors' pathways also appear to present new avenue for the modulation of inflammatory responses and to serve as potential novel therapeutic targets for antiatherosclerotic therapy.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / drug therapy*
  • Cytokines
  • Humans
  • Inflammation
  • Interferon Type I
  • Receptor for Advanced Glycation End Products / drug effects
  • Receptor for Advanced Glycation End Products / physiology*
  • Signal Transduction
  • Toll-Like Receptors / drug effects
  • Toll-Like Receptors / physiology*

Substances

  • Cytokines
  • Interferon Type I
  • Receptor for Advanced Glycation End Products
  • Toll-Like Receptors